AGL

Agilon Health, Inc. (AGL) - Q2 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2026. Agilon Health operates a Medicare-centric, globally capitated line of business through partnerships with physician groups. As of June 30, 2026, the Company provided care to approximately 437,500 Medicare Advantage (MA) members, a 12% decrease from the prior year due to disciplined market exits and a focus on profitability. The Company also manages approximately 112,200 beneficiaries in CMS ACO Models. Notable corporate developments include a 1-for-25 reverse stock split effective March 30, 2026, and the appointment of Tim O'Rourke as CEO and President effective May 7, 2026.

Key Financial Metrics

Note: Debt figures represent the sum of Current Debt ($14,915) and Long-term Debt ($15,377) as of June 30, 2026.

Material Changes vs. Prior Period

• Profitability Turnaround: The Company reported a net income of $18.0 million for Q2 2026, a significant improvement from a net loss of $104.4 million in Q2 2025. This was driven by a shift from a gross loss of $52.4 million to a gross profit of $107.1 million.
• Revenue Growth: Q2 2026 revenue increased 7% year-over-year despite a 10% decline in average MA membership. This was achieved through a 19% increase in PMPM capitation rates due to constructive CMS funding and favorable contract negotiations.
• Expense Management: Medical services expense decreased 10% year-over-year to $1.30 billion, primarily due to the reduction in membership. However, "Other medical expenses" surged to $91.4 million (from $2.2 million) due to $59.7 million in partner physician incentive expenses resulting from improved margins.
• Liquidity Position: Total cash, cash equivalents, and restricted cash stood at $178.8 million. Restricted cash increased to $71.6 million, primarily due to cash collateralization requirements (103%) for outstanding letters of credit under the amended Credit Facility.

Guidance, Outlook, and Risks

Outlook and Commentary: Management emphasizes a disciplined approach to growth, prioritizing profitability over membership expansion. The Company exited certain markets and payor relationships to improve margins. The Credit Facility was amended in early 2026 to extend maturity to 2028 and adjust covenants, though it now requires a minimum of $50 million in total cash and conditions dividend payments on achieving positive EBITDA for two consecutive trailing four-quarter periods.

Risks and Contingencies:

• Legal Proceedings: The Company is involved in multiple securities class action lawsuits (e.g., In re agilon health, inc. Securities Litigation) and shareholder derivative actions alleging misstatements regarding financial guidance and medical margins. Discovery is ongoing, and the Company cannot estimate potential losses.
• Concentration Risk: Revenue is heavily concentrated among a few payors. Payor A and Payor B accounted for 20% and 25% of revenue, respectively, in Q2 2026.
• Regulatory and Operational: Risks include changes in federal healthcare programs, accuracy of risk adjustment estimates, and the ability to retain physician partners.

Key Facts for Investor Verification

• Membership Decline vs. Margin Expansion: Verify the sustainability of margin improvements given the 12% drop in MA members and the strategic decision to exit markets.
• Physician Incentive Payouts: Confirm the timing and magnitude of future partner physician incentive expenses, which spiked in Q2 2026 as margins turned positive.
• Legal Exposure: Monitor the status of the consolidated securities litigation and derivative suits, as outcomes could result in significant financial liability.
• Debt Covenants: Review compliance with the new Credit Facility covenants, specifically the requirement to maintain $50 million in total cash and the EBITDA hurdles for dividend eligibility.
• Reverse Stock Split Impact: Ensure all per-share data and equity awards are correctly adjusted for the 1-for-25 reverse stock split executed in March 2026.